InMed Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Sep 30, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 30, 2024
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| For the Year Ended | ||
|---|---|---|
| June 30, | ||
| 2024 | 2023 | |
| $ | $ | |
| Sales | 4,597,730 | 4,135,561 |
| Cost of sales | 3,496,817 | 2,732,525 |
| Gross profit | 1,100,913 | 1,403,036 |
| Operating Expenses | ||
| Research and development and patents | 3,765,028 | 3,732,056 |
| General and administrative | 5,250,715 | 5,847,518 |
| Amortization and depreciation | 219,600 | 202,249 |
| Foreign Exchange Loss | 61,921 | 48,175 |
| Total operating expenses | 9,297,264 | 9,829,998 |
| Other Income (Expense) | ||
| Interest and other income | 527,901 | 492,440 |
| Loss before income tax expense | (7,668,450) | (7,934,522) |
| Income tax expense | (7,100) | (13,100) |
| Net loss for the year | (7,675,550) | (7,947,622) |
| Net loss per share for the year | ||
| Basic and diluted | (1.01) | (3.25) |
| Weighted average outstanding common shares | ||
| Basic and diluted | 7,621,075 | 2,448,458 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.